# OnCo record paper-capp2-aspirin-lynch-lancet-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-capp2-aspirin-lynch-lancet-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-capp2-aspirin-lynch-lancet-2020" ;
  schema:name "CAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years"@en ;
  schema:description "In carriers of Lynch syndrome, 600 mg of aspirin a day for about two years reduced colorectal cancer over the following decade (HR 0.65 by intention to treat; 0.56 in those who took it for at least two years)."@en ;
  schema:url <https://onco.cc/key-papers/paper-capp2-aspirin-lynch-lancet-2020/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(20)30366-4>, <https://www.isrctn.com/ISRCTN16261285>, <https://pubmed.ncbi.nlm.nih.gov/32534647/>, <https://europepmc.org/article/MED/32534647> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(20)30366-4> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Burn J, Sheth H, Elliott F, et al." ;
  onco:related <https://onco.cc/ideas/idea-prev-lynch-aspirin-implementation/>, <https://onco.cc/ideas/idea-reg-aspirin-pik3ca-implementation/>, <https://onco.cc/key-papers/paper-tcga-colorectal-comprehensive-characterization-nature-2012/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/colon-cancer/>, <https://onco.cc/cancers/msi-high-colorectal/> ;
  onco:sections <https://onco.cc/fronts/prevention/> ;
  onco:technologies <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/technologies/germline-testing/> ;
  onco:drugs <https://onco.cc/drugs/aspirin/> ;
  onco:terms <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/targets/mmr/> ;
  onco:trials <https://onco.cc/trials/capp2/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-hereditary-risk/>, <https://onco.cc/bottlenecks/b-prevention-adoption/>, <https://onco.cc/bottlenecks/b-generic-repurposing/> ;
  onco:journals <https://onco.cc/journals/lancet/> .